Five-year data of continuous Leqembi® treatment show increasing benefit over time

Source
Original press release as distributed by PR Newswire, shown unedited.
Published

STOCKHOLM, Nov. 17, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today presented new five-year data from the Clarity AD study and its long-term extension, showing increasing clinical benefit with continuous Leqembi treatment in early Alzheimer's disease. The data, presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, also showed that 62 percent of patients treated at an earlier stage of disease, with low levels of tau, showed improvement in cognitive function and activities of daily living (CDR-SB[1]), after five years.

Clarity AD is a global, placebo-controlled, double-blind, parallel-group, randomized Phase 3 study involving 1,795 patients with early Alzheimer's disease: 898 in the Leqembi group, receiving 10 mg/kg by intravenous infusion every two weeks, and 897 in the placebo group. Of the patients who completed the 18-month core study, 95% chose to participate in the subsequent long-term extension study. A total of 351 patients received five years of continuous treatment.

Among patients treated continuously with Leqembi for five years, the difference in cognitive and functional decline compared with matched historic Alzheimer's disease data increased over time. Compared with Alzheimer's Disease Neuroimaging Initiative (ADNI)[2] data, patients treated with Leqembi showed 1.00 points less decline on CDR-SB after three years and 2.05 points less decline after five. Compared with BioFINDER[3] data, the corresponding differences were 1.42 points and 2.54 points, respectively. The difference continued to increase over time.

In an assessment based on CDR-SB scores[4], Leqembi reduced the relative risk of progressing to the next stage of Alzheimer's disease by 36 percent compared with ADNI data. After five years, 61.9 percent of Leqembi-treated patients had progressed to the next disease stage, compared with 77.5 percent in ADNI. The relative risk of progressing from early Alzheimer's disease to moderate or severe dementia was reduced by 49 percent, with 31.0 percent of Leqembi-treated patients progressing compared with 48.7 percent in ADNI.

Earlier treatment associated with greater benefit at five years

The Clarity AD study included an optional tau PET substudy to identify patients with low levels of tau accumulation in the brain, indicating an earlier stage of Alzheimer's disease. After five years of continuous Leqembi treatment, 66 percent of patients with low tau showed no decline in cognitive and functional impairment as measured by CDR-SB, while 62 percent showed improvement from baseline. Similar results were also observed on other scales, including ADAS-Cog14 and ADCS MCI-ADL. The results support the importance of initiating treatment early in the course of Alzheimer's disease and continuing treatment to sustain the benefit over time.

Consistent safety profile over five years

No new safety findings were observed during five years of continuous Leqembi treatment. ARIA-E occurred most frequently within the first six months of treatment, with incidences declining in subsequent years. When results were grouped into 12-month treatment intervals, the incidence of ARIA-E was 13.5% during the first 12 months, followed by 3.6%, 1.1%, 1.3%, and 0.6% in subsequent intervals compared with 1.7% in the placebo group over 18 months.

Alzheimer's disease is a progressive, relentless disease with amyloid-beta (Aβ) and tau as hallmarks. It is caused by a continuous underlying neurotoxic process, driven by soluble aggregates of amyloid called protofibrils, that begins before amyloid plaque accumulation and continues after plaque removal. Leqembi fights Alzheimer's disease in two ways – targeting both protofibrils and amyloid plaque.[5],[6],[7]

The information was released for public disclosure, through the agency of the contact person below, on November 17, 2026, at 12:05 am CET.

For further information, please contact: 
Oskar Bosson, Chief Investor Relations & Communications Officer
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

About Leqembi® (lecanemab)

Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Leqembi is approved in 53 countries and is under regulatory review in six countries and regions. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in nine countries and regions, including the US, Japan, China and the United Kingdom, and applications have been filed in eleven countries and regions. In the US, Leqembi Iqlik® is approved for subcutaneous dosing with an autoinjector as a starting dose and maintenance treatment of early Alzheimer's disease. Subcutaneous initiation treatment was approved in China and Japan in September 2026, and applications are under review in four countries.

Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease has been ongoing since July 2020. These individuals are clinically normal and have intermediate or elevated levels of amyloid in their brains. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

About the collaboration between BioArctic and Eisai

BioArctic has a long-term collaboration with Eisai since 2005 regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed in 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed in 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport therapies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

[1] Clinical Dementia Rating – Sum of Boxes (CDR-SB), is a commonly used measure of cognitive and functional impairment in Alzheimer's disease

[2] ADNI is a clinical research project launched in 2005 to develop methods to predict the onset and progression of Alzheimer's disease (AD) and to confirm the effectiveness of treatments. The project involves a multi-year longitudinal observation targeting healthy elderly individuals as well as patients with mild cognitive impairment (MCI) and early stages of AD.

[3] BioFINDER subjects are similar to Study 301 and ADNI subjects, except all BioFINDER subjects are in the MCI stage and no mild AD subjects are included, and their baseline CDR-SB is lower. BioFINDER is a large-scale, long-term prospective study led by Lund University in Sweden, aiming to establish early diagnosis and elucidate pathophysiology of neurodegenerative diseases. In addition to AD, the study also focuses on conditions including Parkinson's disease. Individuals participating in the study undergo regular clinical assessments, cognitive function tests, brain imaging (MRI, Aβ PET, Tau PET), and collection of biomarkers from blood and cerebrospinal fluid (CSF).

[4] Disease-stage progression was assessed using CDR-SB rather than the global CDR to capture changes in disease stage in greater detail, because assessments were conducted at relatively long intervals and control-group data were used to impute missing values. Based on CDR-SB scores, progression was defined as a transition from MCI (0.5–4.0) to mild AD dementia (4.5–9.0) or moderate AD dementia (9.5–15.5). Progression to moderate or severe dementia was defined as a transition to moderate dementia (9.5–15.5) or severe dementia (16.0–18.0), based on the CDR-SB staging criteria.

[5] Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z

[6] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

[7] Hampel H, Hardy J, Blennow K, et al. The amyloid pathway in Alzheimer's disease. Mol Psychiatry. 2021;26(10):5481-5503.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/five-year-data-of-continuous-leqembi--treatment-show-increasing-benefit-over-time,c4425299

The following files are available for download:

https://mb.cision.com/Main/9978/4425299/4375286.pdf

Five-year data of continuous Leqembi® treatment show increasing benefit over time

https://news.cision.com/bioarctic/i/4425299-0-png,c3581089

4425299_0.png

https://news.cision.com/bioarctic/i/4425299-1-png,c3581088

4425299_1.png

 

View original content:https://www.prnewswire.com/news-releases/five-year-data-of-continuous-leqembi-treatment-show-increasing-benefit-over-time-302941328.html

This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.

Not part of the release

AlphAI analysis

ByAlphAI AI DeskAI-generated

Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.

Decision brief

The 30-second read

$BIOABullishMed
01

Why it matters

Five-year Clarity AD extension results with increasing cognitive and functional benefit, plus a consistent safety profile, are intended to strengthen the clinical case for early and continuous treatment.

02

Market read

The release provides new long-term efficacy and safety datapoints that can shift expectations for durability of benefit and treatment adoption for early Alzheimer’s.

03

What to watch

Commercial impact depends on payer uptake, dosing logistics (IV to maintenance and subcutaneous options), and whether ARIA risk remains manageable at scale despite declining incidence over time.

Relevance 8/10Novelty 8/10Timing: conference presentation on Nov. 17, 2026 (CTAD)

Background

Leqembi (lecanemab) is an anti-amyloid monoclonal antibody developed with Eisai; BioArctic commercializes in the Nordic region and receives milestone payments and royalties.

Company-level read

Ticker impact

$BIOABullishMedium confidence
Context

BioArctic’s partner Eisai presented 5-year Clarity AD data showing increasing clinical benefit with continuous Leqembi treatment in early Alzheimer’s.

Expected impact

Likely upward bias as investors price in stronger durability of benefit and reduced perceived clinical risk.

Evidence & confidence

The article reports multi-year efficacy deltas versus ADNI/BioFINDER and a consistent safety profile, which can improve perceived probability of sustained clinical value and commercial uptake.

Market effects

Reinforces the anti-amyloid durability narrative in early Alzheimer’s and may raise the bar for competing efficacy claims over longer follow-up.

Supports European biotech sentiment tied to Alzheimer’s therapeutics and Nordic biopharma partnerships.

Could influence global investor expectations for lecanemab-like mechanisms and long-term extension datasets across major markets.

Counterpoint

The comparisons to ADNI and BioFINDER are not randomized head-to-head controls, so investors may discount the magnitude of the “increasing benefit” claim.

Key entities

  • BioArctic AB

    Swedish biopharma partner for Leqembi; subject of the release via its Leqembi collaboration.

  • Eisai

    Partner responsible for clinical development, regulatory interactions, and commercialization; presented the 5-year data.

  • Leqembi (lecanemab)

    Anti-amyloid monoclonal antibody for early Alzheimer’s; central to the reported Clarity AD extension findings.

  • Clarity AD study

    Phase 3 randomized study with long-term extension; reported 5-year continuous treatment outcomes.